SOLICITATION NOTICE
66 -- Stemgent Dox Lentivirus Set M4F2A Vector
- Notice Date
- 8/3/2010
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-PB-AR-2010-275-CRS
- Archive Date
- 8/25/2010
- Point of Contact
- Caitlin Savina,
- E-Mail Address
-
savinacr@mail.nih.gov
(savinacr@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR PROPOSALS. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. It is the intent of the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) on behalf of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to negotiate/award a purchase order on a noncompetitive sole source basis to Sigma-Aldrich Corporation, 3050 Spruce Street, Saint Louis, MO 63103 for the purchase of 30 Sets of Stemgent Dox Lentivirus M4F2A Vector. The reference number NHLBI-PB-AR-2010-275-CRS. Stemgent will provide 30 sets of proprietary lentivirual vector system for the production of mouse induced Pluriportent Stem (iPS) cells co-developed and distributed through Sigma-Aldrich at a reduced rate. Specifically, Stemgents’s DOX M4F2A vector encodes all four key genes, the mouse Oct4 Sox2 Klf4 and c-Myc (mOKSM), that are routinely used in reprogramming, encoded on a single construct under the control of a tetracycline inducible promoter packaged in a replication deficient lentivirual vector. Supplied on a separate lentiviral vector is the tetracycline transactivator. The licenses for the lentiviral and doxycycline tetracycline technologies are held by Sigma-Aldrich. In addition, Stemgent licensed and commercialized the unique polycistronic iPS technology developed and published by Rudolph Jaenisch at the Massachusetts Institute of Technology (Carey et al., 2008). By delivering all 4 factors on the same construct, this vector mediated reprogramming system greatly simplifies and improves the efficiency of the reprogramming process, while reducing the production of incompletely reprogrammed colonies. Reference: Carey BW, Markoulaki S. Hanna J, Saha K, Gao Q, Miitalipova M and Jaenisch R. Reprogramming of murine and human somatic cells using a single polycistronic vector. 2009. P.N.A.A.; 106 (1): 157-162. The sole source determination is based on the fact that Sigma-Aldrich is the exclusive distributor of this product. No other company currently offers this product that incorporates a unique combination of licensed technologies to reprogram mouse cells into induced pluripotent stem cells. This vector system distributed through Sigma-Aldrich greatly simplifies and improves the efficiency of the reprogramming process. Stemgent fulfills the exacting need that will provide NIH researchers with the kits to facilitate clinical development of iPSCs. The unique capabilities of Stemgent will enable the NIH to begin its mission to create a world class Stem Cell Center. This acquisition is being conducted under FAR Part 13, Simplified Acquisition Procedures, and is exempt from the requirements of FAR Part 6, Competition Requirements. The North American Industry Classification System (NAICS) Code is 334516 and the business size standard is 500 employees. This notice of intent is not a request for competitive proposals. The determination by the Government not to compete the proposed purchase order based upon responses to this notice is solely within the discretion of the Government. Comments to this announcement, referencing synopsis number NHLBI-PB-AR-2010-275-CRS may be submitted by mail to the National Heart, Lung and Blood Institute, Office of Acquisitions, Procurement Branch, 6701 Rockledge Drive, Suite 6150B, Bethesda, MD 20892-7902, Attention: Caitlin Savina, by fax transmission to (301)480-3345 or by email to savinacr@nhlbi.nih.gov This action is under the authority of 41.U.S.C.253(c)(1), as set forth in FAR 13.106(b)(2), and HHSAR 306-302-1. Interested parties responding to this announcement need to do so by 9:00am Eastern Standard Time on August 10, 2010.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-PB-AR-2010-275-CRS/listing.html)
- Place of Performance
- Address: National Institutes of Health/NIAMS, Bethesda, Maryland, 20814, United States
- Zip Code: 20814
- Zip Code: 20814
- Record
- SN02227268-W 20100805/100803235737-5021b57b1163329e6f898fa73dd68a60 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |